GraniteShares 3x Long Moderna Daily ETC (3LMO.L) is a collateralised exchange-traded product (ETP) that provides three times the daily performance of Moderna Inc. (MRNA) stock, excluding fees and expenses, through tracking the Solactive Daily Leveraged 3x Long Moderna Index. Issued by GraniteShares Financial PLC, the ETP employs a fully funded swap replication method and is backed by collateral held in a segregated account by The Bank of New York Mellon SA/NV as custodian; it trades on the London Stock Exchange in USD (ticker: 3LMO) and GBP (ticker: MOL3), with availability in France, Ireland, Italy, and the United Kingdom. The product targets sophisticated investors seeking leveraged exposure to Moderna's biotechnology segment, focusing on mRNA therapeutics and vaccines including Spikevax for COVID-19 and Mresvia for RSV; GraniteShares offers a broader suite of similar leveraged and inverse single-stock ETPs on U.S., UK, and European companies such as NVIDIA, Tesla, AMD, and FAANG baskets. GraniteShares, founded in 2016 and headquartered in New York with European operations based in London, manages over $10.9 billion in assets across ETFs and ETPs listed on exchanges in the U.S., UK, Germany, France, and Italy. In May 2025, the issuer executed a 1-for-5,000 consolidation of 3LMO.L securities effective May 19, updating the ISIN to XS3069877556 and SEDOL codes to BQ82BC8 (USD) and BQ82BH3 (GBX), alongside routine adjustments like those for other ETPs including 3x Short MicroStrategy; recent expansions include new YieldBOOST ETF launches in 2025 targeting quantum computing (RGYY, QBY), Meta, Palantir, and MicroStrategy via options strategies on leveraged underlyings.